Table 1

Baseline demographic and disease characteristics

Cohort 1
Treatment-naive
Cohort 2
Ledipasvir/sofosbuvir or sofosbuvir-experienced
Cohort 3
Interferon-experienced
Ledipasvir/
sofosbuvir
8 weeks
(n=43)
Ledipasvir/
sofosbuvir+ ribavirin
8 weeks
(n=42)
Ledipasvir/
sofosbuvir
12 weeks
(n=43)
Ledipasvir/
sofosbuvir+ribavirin
12 weeks
(n=42)
Ledipasvir/
sofosbuvir+ribavirin
12 weeks
(n=11)
Ledipasvir/
sofosbuvir
12 weeks
(n=36)
Ledipasvir/
sofosbuvir+ribavirin
12 weeks
(n=38)
Mean age, years (range)53
(22–74)
49
(23–71)
49
(23–74)
46
(21–68)
48
(23–72)
49
(24–67)
51
(29–74)
Male, n (%)25 (58)22 (52)22 (51)22 (52)8 (73)32 (89)25 (66)
Mean BMI, kg/m2 (range)30.0
(22.0–50.0)
31.4
(23.9–45.9)
30.8
(21.0–45.7)
29.5
(22.8–39.4)
33.9
(23.6–50.8)
29.1
(19.1–42.6)
28.1
(20.3–37.1)
Cirrhosis, n (%)7 (16)7 (17)9 (21)8 (19)3 (27)10 (28)10 (26)
IL28B non-CC genotype, n (%)31 (72)37 (88)32 (74)33 (79)11 (100)31 (86)30 (79)
HCV RNA
 Mean, log10 IU/mL (range)6.0
(4.7–7.0)
5.6
(3.7–6.8)
5.7
(4.3–7.0)
5.8
(4.3–7.1)
6.2
(5.2–7.0)
5.8
(1.1–7.3)
5.8
(1.8–7.2)
 ≥6 000 000 IU/mL, n (%)2 (5)02 (5)4 (10)3 (27)2 (6)4 (11)
Response to prior HCV treatment, n (%)
 Non-responseNANANANA018 (50)21 (55)
 Relapse/breakthroughNANANANA11 (100)16 (44)17 (45)
 Interferon-intolerantNANANANA02 (6)0
  • BMI, body mass index; HCV, hepatitis C virus; NA, not applicable.